Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524

MedImmune

Status and phase

Completed

Phase 2

Phase 1

Conditions

Respiratory Syncytial Virus Infections

Treatments

Biological: Medi-524

Study type

Interventional

Funder types

Industry

Identifiers

NCT00192478

MI-CP104

Details and patient eligibility

About

MEDI-524 given for up to 5 doses at 3 and 15 mg/kg to high-risk children appeared to be safe and well tolerated.

Full description

This study is designed to describe the safety, tolerability, immunogenicity, and pharmacokinetics of escalating, repeated IM injections (the intended route of administration for immunoprophylaxis) of MEDI-524, initially in children £6 months old with a history of prematurity (³32 to £35 weeks gestation, without BPD), one of the target populations of infants at high risk for serious RSV disease.

Enrollment

217 patients

Sex

All

Ages

6 to 24 months old

Volunteers

No Healthy Volunteers

Inclusion criteria

All male or female children must have met all the following criteria:
[Groups 1, 2, and 3] The child must have been born at ³32 to £35 weeks gestation and have been £6 months of age at the time of entry into the study (child must have been entered on or before their 6-month birthday) or [Group 3 only] The child must have been £24 months of age at the time of entry into the study (child must have been entered on or before their 24-month birthday) and diagnosed with BPD, with stable or decreasing doses of diuretics, steroids, or bronchodilators within the previous 6 months
The child must have been in general good health at the time of entry
The child's parent or legal guardian must have provided written informed consent; and
The child must have been able to complete the follow-up visits through 90 days following last injection of MEDI-524
Parent/legal guardian of patient must have had available telephone access

Exclusion criteria

Children must have had none of the following:
Hospitalization at the time of study entry (unless discharge was expected within 3 days after entry into the study)
[All children in Groups 1 and 2; only children £6 months of age in Group 3] Birth hospitalization >6 weeks duration or [Only children >6 months of age in Group 3] Birth hospitalization >12 weeks duration
Been receiving chronic oxygen therapy or mechanical ventilation at the time of study entry (including CPAP)
[Groups 1 and 2 only] Diagnosis of BPD, defined as history of prematurity and associated chronic lung disease with oxygen requirement for >28 days
Congenital heart disease (CHD) (Children with medically or surgically corrected [closed] patent ductus arteriosus and no other CHD may be enrolled)
Evidence of infection with hepatitis A, B, or C virus
Known renal impairment, hepatic dysfunction, chronic seizure disorder, or immunodeficiency or HIV infection
Mother with known HIV infection
Any of the following laboratory findings in blood obtained within 7 days prior to study entry: BUN or creatinine >1.5´ the upper limit of normal for age; AST (SGOT) or ALT (SGPT) >1.5´ the upper limit of normal for age; hemoglobin <9.5 gm/dL; white blood cell count <4,000 cells/mm3; platelet count <120,000 cells/mm3
Acute illness or progressive clinical disorder
Active infection, including acute RSV infection
Previous reaction to IGIV, blood products, or other foreign proteins
Have ever received palivizumab
Received within the past 120 days or currently receiving immunoglobulin products (such as RSV-IGIV [RespiGamÒ], IVIG), or any investigational agents
Currently participating in any investigational study
Previously participated in any investigational study of RSV vaccines or monoclonal antibodies.